Becton, Dickinson beat on Life Sciences revenue +31% driven by strong COVID-19 testing

• Becton, Dickinson (NYSE:BDX) fiscal Q4 results:
• Revenues: $4,784M (+4.4%); BD Medical: $2,318M (-4.9%); BD Life Sciences: $1,488MM (+31.2%); BD Interventional: $978M (-3.4%).
• BD Life Sciences sales were driven by strong sales related to COVID-19 diagnostic testing solutions in the Diagnostic Systems unit on the BD Veritor and BD Max platforms.
• Net Income: $105M (-15.9%); EPS: $0.36 (-20.0%); non-GAAP EPS: $2.79 (-15.7%).
• CF Ops: $3,539M (+6.3%).
• FY 2021 Guidance: Revenue growth: high single to low double-digits; non-GAAP EPS: non-GAAP EPS: $12.40 - 12.60 (consensus: $12.53).
• https://seekingalpha.com/news/3631911-becton-dickinson-beats-fq4-consensus-life-sciences-revenueplus-31-driven-strong-covidminus-19